Status:
COMPLETED
QUILT-2.015: A Study of AMG 479 With Exemestane or Fulvestrant in Postmenopausal Women With Hormone Receptor Positive Locally Advanced or Metastatic Breast Cancer
Lead Sponsor:
NantCell, Inc.
Conditions:
Breast Cancer
Breast Tumors
Eligibility:
FEMALE
18+ years
Phase:
PHASE2
Brief Summary
This is a randomized, double-blind, placebo-controlled, phase 2 study. Subjects will include postmenopausal women with confirmed HR-positive, locally advanced or metastatic breast cancer, who have dis...
Eligibility Criteria
Inclusion
- Histologically or cytologically confirmed carcinoma of the breast with locally advanced or metastatic disease
- Confirmation of hormone receptor (HR) positive disease status
- Amenable to receive endocrine therapy
- Disease progression while receiving prior endocrine therapy for locally advanced or metastatic breast cancer
- Postmenopausal woman ≥ 18 years old
Exclusion
- HR-unknown or HR-negative disease
- Not amenable to endocrine therapy
- Central nervous system metastasis
Key Trial Info
Start Date :
March 27 2008
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
September 23 2011
Estimated Enrollment :
156 Patients enrolled
Trial Details
Trial ID
NCT00626106
Start Date
March 27 2008
End Date
September 23 2011
Last Update
September 19 2024
Active Locations (60)
Enter a location and click search to find clinical trials sorted by distance.
1
Research Site
Chandler, Arizona, United States, 85224
2
Research Site
Anaheim, California, United States, 92801
3
Research Site
Beverly Hills, California, United States, 90211
4
Research Site
Concord, California, United States, 94520